Clinical trials for patients with cancer in the tissue of one or both lungs
If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information.
For more information on upper gastrointestinal cancer clinical trials, get in contact with our Monc B team
Trial ID Cancer type Non-small Cell Lung Cancer Status Open and recruiting Phase Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the ClinicalTrials.gov.
V940-002
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II-IIIB (N2) Non-small Cell Lung Cancer
Trial ID Cancer type Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation Status Open and recruiting Phase Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the ClinicalTrials.gov Registry.
WU KONG28S
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Trial ID Cancer type PD-L1-negative Non-Small Cell Lung Cancer with KRAS p.G12C Mutation Status Open and recruiting Phase Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the ClinicalTrials.gov.
Codebreak 202
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C
Trial ID Cancer type Non-Small Cell Lung Cancer Status Open and recruiting Phase Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types. Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
OCEANiC
A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Following Complete Surgical Resection
Trial ID Cancer type Non-Small Cell Lung Cancer with KRAS G12C Mutation Status Open and recruiting Phase Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
SHERLOCK
Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
Trial ID Cancer type ALK-positive Non-Small Cell Lung Cancer Status Open and recruiting Phase Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ALKOVE-1
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumours
Trial ID Cancer type Non-Small Cell Lung Cancer Status Open and recruiting Phase Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type. Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
PACIFIC-9
A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Trial ID Cancer type Non-Small Cell Lung Cancer Status Open and recruiting Phase Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
BO42777
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts Of Patients Selected According to Biomarker status, with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Trial ID Cancer type Lung Cancer Status Open and recruiting Phase Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
BX43361
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Trial ID Cancer type ROS1-positive Non-Small Cell Lung Cancer and Other Solid Cancers Status Open and recruiting Phase Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ARROS-1
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors
Trial ID Cancer type Mesothelioma Status Open and recruiting Phase Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients. Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
CIAG933A12101
An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors
Title A Phase 1a\1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Trial ID Cancer type Non-Small Cell Lung Cancer with KRAS G12C Mutation Status Open and recruiting Phase Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients. Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the ClinicalTrials.gov.
Trial ID Cancer type Mesothelioma Status Open and recruiting Phase Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients. Who can participate Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Vivace
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VT3989 in Patients with Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)